tetano
Editor, Senior Moderator
Drug Dev Res
. 2020 Jul 6.
doi: 10.1002/ddr.21709. Online ahead of print.
Revisiting Potential Druggable Targets Against SARS-CoV-2 and Repurposing Therapeutics Under Preclinical Study and Clinical Trials: A Comprehensive Review
Abdullah Al Mamun Sohag[SUP] 1 [/SUP], Md Abdul Hannan[SUP] 1 2 3 [/SUP], Sadaqur Rahman[SUP] 4 [/SUP], Motaher Hossain[SUP] 5 [/SUP], Mahmudul Hasan[SUP] 6 [/SUP], Md Kawsar Khan[SUP] 4 7 [/SUP], Amena Khatun[SUP] 8 [/SUP], Raju Dash[SUP] 2 [/SUP], Md Jamal Uddin[SUP] 3 9 [/SUP]
Affiliations
Abstract
Coronavirus disease-19 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is one of the most contagious diseases in human history that has already affected millions of lives worldwide. To date, no vaccines or effective therapeutics have been discovered yet that may successfully treat COVID-19 patients or contain the transmission of the virus. Scientific communities across the globe responded rapidly and have been working relentlessly to develop drugs and vaccines, which may require considerable time. In this uncertainty, repurposing the existing antiviral drugs could be the best strategy to speed up the discovery of effective therapeutics against SARS-CoV-2. Moreover, drug repurposing may leave some vital information on druggable targets that could be capitalized in target-based drug discovery. Information on possible drug targets and the progress on therapeutic and vaccine development also needs to be updated. In this review, we revisited the druggable targets that may hold promise in the development of the anti-SARS-CoV-2 agent. Progresses on the development of potential therapeutics and vaccines that are under the preclinical studies and clinical trials have been highlighted. We anticipate that this review will provide valuable information that would help to accelerate the development of therapeutics and vaccines against SARS-CoV-2 infection.
Keywords: COVID-19; clinical trial; drug repurposing; drug targets; therapeutics; vaccines.
. 2020 Jul 6.
doi: 10.1002/ddr.21709. Online ahead of print.
Revisiting Potential Druggable Targets Against SARS-CoV-2 and Repurposing Therapeutics Under Preclinical Study and Clinical Trials: A Comprehensive Review
Abdullah Al Mamun Sohag[SUP] 1 [/SUP], Md Abdul Hannan[SUP] 1 2 3 [/SUP], Sadaqur Rahman[SUP] 4 [/SUP], Motaher Hossain[SUP] 5 [/SUP], Mahmudul Hasan[SUP] 6 [/SUP], Md Kawsar Khan[SUP] 4 7 [/SUP], Amena Khatun[SUP] 8 [/SUP], Raju Dash[SUP] 2 [/SUP], Md Jamal Uddin[SUP] 3 9 [/SUP]
Affiliations
- PMID: 32632960
- DOI: 10.1002/ddr.21709
Abstract
Coronavirus disease-19 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is one of the most contagious diseases in human history that has already affected millions of lives worldwide. To date, no vaccines or effective therapeutics have been discovered yet that may successfully treat COVID-19 patients or contain the transmission of the virus. Scientific communities across the globe responded rapidly and have been working relentlessly to develop drugs and vaccines, which may require considerable time. In this uncertainty, repurposing the existing antiviral drugs could be the best strategy to speed up the discovery of effective therapeutics against SARS-CoV-2. Moreover, drug repurposing may leave some vital information on druggable targets that could be capitalized in target-based drug discovery. Information on possible drug targets and the progress on therapeutic and vaccine development also needs to be updated. In this review, we revisited the druggable targets that may hold promise in the development of the anti-SARS-CoV-2 agent. Progresses on the development of potential therapeutics and vaccines that are under the preclinical studies and clinical trials have been highlighted. We anticipate that this review will provide valuable information that would help to accelerate the development of therapeutics and vaccines against SARS-CoV-2 infection.
Keywords: COVID-19; clinical trial; drug repurposing; drug targets; therapeutics; vaccines.